Are you newly diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and looking for treatment options? Our study is evaluating new therapies specifically designed for patients with these conditions. If you have not previously tried an anti-cancer therapy for AML/MDS, this study might be for you!

Do you have a solid tumor that has progressed on other treatments? Do you have at least one measurable tumor? If so, you may be able to take part in a study to improve treatment for advanced solid tumors. We are exploring how safe and effective a combination of drugs is.

The purpose of this study is to interview breast cancer survivors in North Carolina to understand how various factors have impacted their emotional well-being

Have you been diagnosed with a neuroendocrine cancer that has not responded to other treatment options? If so then you may be eligible to participate in a study to examine the safety and effectiveness of a new cancer therapy designed to target specific neuroendocrine tumors cells.

Have you been diagnosed with cancer? If so, you may have the opportunity to participate in a research study designed to examine how central oncology navigation affects the use of supportive care services. Additionally, the study will assess whether enrollment in non-treatment clinical trials increases with the implementation of an Oncology Navigation Resource (ORN) intervention.

Do you have a new diagnosis of Leukemia? If so, you may be able to take part in a research study on a new drug called Quizartinib. We want to see if this new drug helps treat Leukemia better. Compensation provided.

Do you have T-cell Lymphoma? Is your disease relapsed or refractory and CD5 positive? If so, you may be able to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Do you have incurable, metastatic/recurrent head and neck squamous cell carcinoma? If so, you may be able to take part in a study to see if a new drug called petosemtamab is effective. We want to see if petosemtamab works better than the treatments doctors usually use for head and neck squamous cell carcinoma. Compensation provided.

This study is being done to look at the effects of an investigational drug, RP1, in patients with organ and hematopoietic cell transplant with advanced skin cancer (cutaneous squamous cell carcinoma).

In this study, we want to asses the long-term safety of using a virus to deliver a gene, AAV2-hAQP1, and how effective this gene is at treating dry mouth in people who have received radiation therapy for head and neck cancer.